N/A
N=2,738,161
Epidemiologic Study Of Diabetes And Cancer Risk
Diabetes Mellitus, Type 2, Cancer
Bottom Line
View on ClinicalTrials.gov: NCT02958995 ↗Enrolled (actual)
2,738,161
Serious AEs
—
Results posted
Mar 2017
Primary outcome: Primary: Age and Sex-Standardized Incidence Rates for the 10 Most Common Cancers Stratified by Diabetes Status — 380.2; 421.9; 308.0; 281.9 Incidence per 100,000 person-years
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- No Intervention (Other)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- Takeda
- Primary completion
- May 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Age and Sex-Standardized Incidence Rates for the 10 Most Common Cancers Stratified by Diabetes Status |
380.2; 421.9; 308.0; 281.9; 291.8; 310.7 | — |
| PRIMARY Hazard Ratio for Risk of 10 Common Cancers Associated With Diabetes |
0.81; 0.77; 1.01; 0.98; 0.99; 0.84 | — |
Summary
The purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes along with the assessment of association between diabetes severity and cancer risk.
Eligibility Criteria
Inclusion Criteria: 1. has been in the KPNC diabetes registry Diabetes Mellitus (DM) registry, aged 40 years or older and are members of KPNC as of January 1, 1997 and had no prior diagnosis of the cancer of interest.
Data sourced from ClinicalTrials.gov (NCT02958995). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.